10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology
"The new products we have planned for 2024 will take 10x to the next level, as we deliver game-changing new technologies that will redefine the Visium, Xenium and Chromium platforms," said
Visium Spatial Analysis
10x Genomics recently announced the launch of Visium HD, a new product that enables whole transcriptome spatial discovery at single-cell scale resolution. At AGBT, the company will share new data to highlight the performance advantages of Visium HD, which is now available for pre-order and is expected to start shipping this quarter.
"Visium HD will be a powerful tool for spatial discovery, empowering scientists to study the organization and interactions of cells in real-world tissue samples with a high degree of detail across the whole transcriptome," added Hindson. "The resolution opens up the possibility to disaggregate what is happening within niches and discover patterns and pathways in fine structures, offering a complete view of the transcriptome with spatial context."
Xenium In Situ Analysis
In its first full year of launch, the company's Xenium In Situ platform has seen rapid growth and adoption, with more than 250 Xenium instruments sold and multiple independent benchmarking studies demonstrating Xenium is the best performing platform for in situ analysis.
At AGBT, 10x will share the latest data from the company's comprehensive Xenium product roadmap, including:
- Multimodal cell segmentation, a new add-on kit compatible with existing Xenium reagents to enable improved biological interpretation, which is expected to begin shipping in Q1 2024.
- Xenium 5,000-plex panel, which delivers a massive codebook expansion while maintaining the platform's high specificity, per-gene sensitivity and throughput. The new 5,000-plex kit, which can analyze 4 cm2 of tissue in six days, is expected to start shipping in Q2 2024.
- Integrated Xenium Protein Profiling, a new assay expected in the second half of the year, which will enable multiplex protein detection and gene expression analysis on the same tissue section in a single run.
Chromium Single Cell Analysis
At AGBT,
- Whole blood fixation to directly fix whole blood for storage and later use with the Flex assay.
- Intracellular protein profiling to simultaneously analyze gene expression and intracellular proteins including cytokines and phospho-proteins.
- CRISPR/sgRNA screens to enable functional genetic screens at scale and low cost.
At its
Posters and Featured Talks
Throughout AGBT,
-
Sponsor Workshop : Mind blowing science enabled by industry-leading single cell & spatial technologies (February 7, 2024 ). Register for the livestream here. - Featured Posters:
- Poster 301: A blood collection workflow for interrogation of translational samples with single-cell technologies
- Poster 537: Cell boundary segmentation for the Xenium Analyzer
- Poster 583: In situ detection and subcellular localization of 5,000 genes using Xenium Analyzer
- Poster 626: Scaling high-throughput, multimodal single cell CRISPR screens using 10x Genomics Chromium Single Cell Gene Expression Flex
- Poster 654: Visium HD enables whole-transcriptome spatial profiling at single cell scale resolution in formalin-fixed, paraffin embedded (FFPE) tissues
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding
Disclosure Information
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-showcase-new-cutting-edge-technologies-and-highlight-innovation-roadmap-at-2024-agbt-general-meeting-302053701.html
SOURCE